CINCINNATI, Sept. 20, 2016 (GLOBE NEWSWIRE) — Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the SensiFAST Lyo-Ready No-ROX Mix from Bioline to add to the SensiFAST family of real-time PCR products.
Bioline has developed a ready-to-use, lyophilization-compatible qPCR mix, the SensiFAST Lyo-Ready No-ROX Mix. The SensiFAST Lyo-Ready No-ROX Mix has exactly the same fast, highly reproducible performance as the SensiFAST ‘wet’ formulation, however the SensiFAST Lyo-Ready No-ROX Mix can be lyophilized with customer supplied assay-specific primers and probes and stored at room temperature, making it ideal for automated, high throughput systems.
Marco Calzavara, President of Bioline commented, “I am delighted to announce the release of SensiFAST Lyo-Ready No-ROX Mix as a new member of our real-time PCR-based SensiFAST family. This new mix will enable researchers to lyophilize and store their real-time PCR assays at room temperature, reducing the risks associated with storage and shipping requirements.”
Richard L. Eberly, President, Chief Commercial Officer, stated, “We are delighted to release the SensiFAST Lyo-Ready No-ROX Mix as it is ideal for in-vitro diagnostic manufacturers, clinical diagnostic laboratories, Biotech and biopharmaceutical companies, in reducing cold storage space, product and time wastage, while maintaining the sensitivity and reproducibility expected with the SensiFAST qPCR kits. We remain committed to bringing innovation and quality products such as the SensiFAST Lyo-Ready No-ROX Mix to our research and industrial customers around the world.”
About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections and blood lead levels. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections; serology, parasitology and fungal disease diagnosis, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and biotech companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
For Additional information:
For more information about Bioline, please visit http://www.bioline.com.
CONTACT: Richard L. Eberly President, Chief Commercial Officer Meridian Bioscience, Inc. Phone: 513.271.3700 [email protected]